Calcium homeostasis in health and in kidney disease

Comprehensive Physiology

Volumn 6, Issue 4, 2016, Pages 1781-1800

  Moe, Sharon M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM;

ANIMAL; HOMEOSTASIS; HUMAN; KIDNEY DISEASE; METABOLISM;

ANIMALS; CALCIUM; HOMEOSTASIS; HUMANS; KIDNEY DISEASES;

EID: 85021085362     PISSN: None     EISSN: 20404603     Source Type: Journal    
DOI: 10.1002/cphy.c150052     Document Type: Article

References (213)

1. Alexander RT, Dimke H, Cordat E. Proximal tubular NHEs: Sodium, protons and calcium? Am J Physiol Renal Physiol 305: F229-F236, 2013
2. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294: 184-188, 1976
3. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure [see comments]. N Engl J Med 321: 274-279, 1989
4. Ba J, Brown D, Friedman PA. Calcium-sensing receptor regulation of PTH-inhibitable proximal tubule phosphate transport. Am J Physiol Renal Physiol 285: F1233-F1243, 2003
5. Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, Adams JS, Salusky IB, HewisonM. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1, 25-dihydroxyvitamin D in human monocytes. J Bone Miner Res 28: 46-55, 2013
6. Bacic D, LehirM, Biber J, Kaissling B, Murer H, Wagner CA. The renal Na+/phosphate cotransporter NaPi-IIa is internalized via the receptormediated endocytic route in response to parathyroid hormone. Kidney Int 69: 495-503, 2006
7. Baker LR, Abrams SM, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH. Early therapy of renal bone disease with calcitriol: A prospective double-blind study. Kidney Int Suppl 27: S140-S142, 1989
8. Baron R, KneisselM. WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat Med 19: 179-192, 2013
9. Bellido T, Saini V, Pajevic PD. Effects of PTH on osteocyte function. Bone 54: 250-257, 2013
10. Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol 5: pii: a015958, 2013
11. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117: 4003-4008, 2007
12. Benn BS, Ajibade D, Porta A, Dhawan P, Hediger M, Peng JB, Jiang Y, Oh GT, Jeung EB, Lieben L, Bouillon R, Carmeliet G, Christakos S. Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin-D9k. Endocrinology 149: 3196-3205, 2008
13. Bergsland KJ, Coe FL, Gillen DL, Worcester EM. A test of the hypothesis that the collecting duct calcium-sensing receptor limits rise of urine calcium molarity in hypercalciuric calcium kidney stone formers. Am J Physiol Renal Physiol 297: F1017-F1023, 2009
14. Berndt TJ, Schiavi S, Kumar R. 'Phosphatonins' and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289: F1170-F1182, 2005
15. Bleyer AJ, Burke SK, DillonM, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33: 694-701, 1999
16. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
17. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, ZaniVJ, Olson KA, Drueke TB, GoodmanWG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004
18. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824, 2005
19. Boros S, Bindels RJ, Hoenderop JG. Active Ca(2+) reabsorption in the connecting tubule. Pflugers Arch 458: 99-109, 2009
20. Boskey AL, Gadaleta S, Gundberg C, Doty SB, Ducy P, Karsenty G. Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 23: 187-196, 1998
21. Brennan SC, Davies TS, SchepelmannM, Riccardi D. Emerging roles of the extracellular calcium-sensing receptor in nutrient sensing: Control of taste modulation and intestinal hormone secretion. Br J Nutr 111, S16-S22, 2014
22. Bronner F. Recent developments in intestinal calcium absorption. Nutr Rev 67: 109-113, 2009
23. 3 and BCI-210 suppress PTHsecretion by bovine parathyroid cells. Nephrol Dial Transplant 21: 644-650, 2006
24. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. JClin Endocrinol Metab 56: 572-581, 1983
25. 2+ and other ions as extracellular (first) messengers. Physiol Rev 71: 371-411, 1991
26. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366: 575-580, 1993
27. Brown EM, Katz C, Butters R, Kifor O. Polyarginine, polylysine, and protamine mimic the effects of high extracellular calcium concentrations on dispersed bovine parathyroid cells. J Bone Miner Res 6: 1217-1225, 1991
28. Brown EM, Pollak M, Chou YH, Seidman CE, Seidman JG, Hebert SC. Cloning and functional characterization of extracellular Ca(2+)-sensing receptors from parathyroid and kidney. Bone 17: 7S-11S, 1995
29. Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A, NabeshimaY, Reyes-Mugica M, Carpenter TO, Lifton RP. Atranslocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 105: 3455-3460, 2008
30. Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, Munoz-Castaneda JR, Shalhoub V, Almaden Y, RodriguezM. FGF23 fails to inhibit uremic parathyroid glands. JAm Soc Nephrol 21: 1125-1135, 2010
31. Capuano P, Bacic D, Stange G, Hernando N, Kaissling B, Pal R, Kocher O, Biber J, Wagner CA, MurerH. Expression and regulation of the renal Na/phosphate cotransporter NaPi-IIa in amousemodel deficient for the PDZ protein PDZK1. Pflugers Arch 449: 392-402, 2005
32. Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: Circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 95: E352-E357, 2010
33. Cha SK, Jabbar W, Xie J, Huang CL. Regulation of TRPV5 singlechannel activity by intracellular pH. J Membr Biol 220: 79-85, 2007
34. Cha SK, Kim JH, Huang CL. Flow-induced activation of TRPV5 and TRPV6 channels stimulates Ca(2+)-activated K(+) channel causing membrane hyperpolarization. Biochim Biophys Acta 1833: 3046-3053, 2013
35. Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 310: 490-493, 2005
36. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46: 58-67, 2005
37. ChertowGM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
38. Coburn JW, Hartenbower DL, Massry SG. Intestinal absorption of calcium and the effect of renal insufficiency. Kidney Int 4: 96-104, 1973
39. Coburn JW, KoppelMH, Brickman AS, Massry SG. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 3: 264-272, 1973
40. Cochran M, Bulusu L, Horsman A, Stasiak L, Nordin BE. Hypocalcaemia and bone disease in renal failure. Nephron 10: 113-140, 1973
41. Conigrave AD, Ward DT. Calcium-sensing receptor (CaSR): Pharmacological properties and signaling pathways. Best Pract Res Clin Endocrinol Metab 27: 315-331, 2013
42. Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J AmSoc Nephrol 13: 2299-2308, 2002
43. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64: 1653-1661, 2003
44. Cross HS. Extrarenal vitamin D hydroxylase expression and activity in normal and malignant cells: Modification of expression by epigenetic mechanisms and dietary substances. Nutr Rev 65: S108-S112, 2007
45. Crouthamel MH, Lau WL, Leaf EM, Chavkin NW, Wallingford MC, Peterson DF, Li X, Liu Y, Chin MT, Levi M, Giachelli CM. Sodiumdependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: Redundant roles for PiT-1 and PiT-2. Arterioscler Thromb Vasc Biol 33: 2625-2632, 2013
46. D'Amour P. Acute and chronic regulation of circulating PTH: Significance in health and in disease. Clin Biochem 45: 964-969, 2012
47. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl S73-S78, 2003
48. Danese MD, Halperin M, Lowe KA, Bradbury BD, Do TP, Block GA. Refining the definition of clinically important mineral and bone disorder in hemodialysis patients. Nephrol Dial Transplant 30: 1336-1344, 2015
49. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 22: 1603-1609, 2011
50. Deliot N, Hernando N, Horst-Liu Z, Gisler SM, Capuano P, Wagner CA, Bacic D, O'Brien S, Biber J, Murer H. Parathyroid hormone treatment induces dissociation of type IIa Na+-P(i) cotransporter-Na+/H +exchanger regulatory factor-1 complexes. Am J Physiol Cell Physiol 289: C159-C167, 2005
51. Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 28: 596-602, 1996
52. Dewberry K, Fox J, Stewart J, Murray J, Hutchison AJ. Lanthanum carbonate: A novel non-calcium containing phosphate binder. J Amer Soc Neph 8: A2610, 1997
53. Di Marco GS, Reuter S, Kentrup D, Grabner A, Amaral AP, Fobker M, Stypmann J, Pavenstadt H, Wolf M, Faul C, Brand M. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animalmodel of CKD. Nephrol Dial Transplant 29: 2028-2035, 2014
54. Diaz de Barboza G, Guizzardi S, Tolosa de Talamoni N. Molecular aspects of intestinal calcium absorption. World J Gastroenterol 21: 7142-7154, 2015
55. Dimke H, Desai P, Borovac J, Lau A, PanW, Alexander RT. Activation of the Ca(2+)-sensing receptor increases renal claudin-14 expression and urinary Ca(2+) excretion. Am J Physiol Renal Physiol 304: F761-F769, 2013
56. Divieti P, John MR, Juppner H, Bringhurst FR. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143: 171-176, 2002
57. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation [see comments]. Cell 89: 747-754, 1997
58. Dunlay R, Hruska K. PTH receptor coupling to phospholipase C is an alternate pathway of signal transduction in bone and kidney. Am J Physiol 258: F223-F231, 1990
59. Dusso AS, Finch J, Brown A, Ritter C, Delmez J, Schreiner G, Slatopolsky E. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 72: 157-164, 1991
60. Dusso AS, Negrea L, Gunawardhana S, Lopez-Hilker S, Finch J, Mori T, Nishii Y, Slatopolsky E, Brown AJ. On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128: 1687-1692, 1991
61. 2 vitaminD3 in vivo independently of parathyroid hormone. Am J Physiol Renal Physiol 297: F720-F728, 2009
62. Farrow EG, Davis SI, Summers LJ, White KE. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20: 955-960, 2009
63. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
64. Feng JQ, Clinkenbeard EL, Yuan B, White KE, Drezner MK. Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia. Bone 54: 213-221, 2013
65. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77: 211-218, 2010
66. Gardiner EM, Baldock PA, Thomas GP, Sims NA, Henderson NK, Hollis B, White CP, Sunn KL, Morrison NA, Walsh WR, Eisman JA. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J 14: 1908-1916, 2000
67. Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, Baum M. FGF23 decreases renalNaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 297: F282-F291, 2009
68. GauciC, Moranne O, FouquerayB, de la Faille R, MaruaniG, Haymann JP, Jacquot C, Boffa JJ, Flamant M, Rossert J, Urena P, Stengel B, Souberbielle JC, Froissart M, Houillier P. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 19: 1592-1598, 2008
69. Giachelli CM. Vascular calcification: In vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14: S300-S304, 2003
70. GkikaD, Topala CN, Chang Q, PicardN, Thebault S, Houillier P, Hoenderop JG, Bindels RJ. Tissue kallikrein stimulates Ca(2+) reabsorption via PKC-dependent plasma membrane accumulation of TRPV5. EMBO J 25: 4707-4716, 2006
71. Glendenning P. It is time to start ordering ionized calcium more frequently: Preanalytical factors can be controlled and postanalytical data justify measurement. Ann Clin Biochem 50: 191-193, 2013
72. Goltzman D. Inferences from genetically modified mouse models on the skeletal actions of vitamin D. J Steroid Biochem Mol Biol 148: 219-224, 2015
73. Gong Y, Hou J. Claudin-14 underlies Ca(+)(+)-sensing receptormediated Ca(+)(+) metabolism via NFAT-microRNA-based mechanisms. J Am Soc Nephrol 25: 745-760, 2014
74. Gong Y, Renigunta V, Himmerkus N, Zhang J, Renigunta A, Bleich M, Hou J. Claudin-14 regulates renal Ca(+)(+) transport in response to CaSR signalling via a novel microRNA pathway. EMBO J 31: 1999-2012, 2012
75. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstadt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22: 1020-1032, 2015
76. Graciolli FG, Neves KR, dos Reis LM, Graciolli RG, Noronha IL, Moyses RM, Jorgetti V. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant 24: 1416-1421, 2009
77. Groschel C, Tennakoon S, Kallay E. Cytochrome P450 vitamin D hydroxylases in inflammation and cancer. Adv Pharmacol 74: 413-458, 2015
78. Gunzel D, Haisch L, Pfaffenbach S, Krug SM, Milatz S, Amasheh S, Hunziker W, Muller D. Claudin function in the thick ascending limb of Henle's loop. Ann N Y Acad Sci 1165: 152-162, 2009
79. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552, 2009
80. Gutierrez OM, MannstadtM, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, WolfM. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
81. Healy MD, Malluche HH, Goldstein DA, Singer FR, Massry SG. Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch Intern Med 140: 1030-1033, 1980
82. Heaney R, Skillman T. Secretion and excretion of calcium by the human gastrointestinal tract. J Lab & Clin Med 64: 29-41, 1964
83. Hendy GN, D'Souza-Li L, Yang B, Canaff L, Cole DE. Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat 16: 281-296, 2000
84. Hendy GN, Hruska KA, Mathew S, Goltzman D. New insights into mineral and skeletal regulation by active forms of vitamin D. Kidney Int 69: 218-223, 2006
85. Hill KM, Martin BR, WastneyME, McCabe GP, Moe SM, Weaver CM, Peacock M. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 83: 959-966, 2012
86. 2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 112: 1906-1914, 2003
87. 2+ channels TRPV5 and TRPV6. EMBO J 22: 776-785, 2003
88. Hoorn EJ, Zietse R. Disorders of calcium and magnesium balance: A physiology-based approach. Pediatr Nephrol 28: 1195-1206, 2013
89. Hu MC, Kuro-o M, Moe OW. Renal and extrarenal actions of Klotho. Semin Nephrol 33: 118-129, 2013
90. Hu MC, Shi M, Cho HJ, Adams-Huet B, Paek J, Hill K, Shelton J, Amaral AP, Faul C, Taniguchi M, Wolf M, Brand M, Takahashi M, Kuro OM, Hill JA, Moe OW. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 26: 1290-1302, 2015
91. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, Razzaque MS, Rosenblatt KP, Baum MG, Kuro-o M, Moe OW. Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 24: 3438-3450, 2010
92. Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, GoodmanWG, HerzogCA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: 2482-2494, 2012
93. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20: 388-396, 2009
94. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
95. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
96. Jiang Y, Ferguson WB, Peng JB. WNK4 enhances TRPV5-mediated calcium transport: Potential role in hypercalciuria of familial hyperkalemic hypertension caused by genemutation ofWNK4. Am J Physiol Renal Physiol 292: F545-554, 2007
97. Jones G. Extrarenal vitamin D activation and interactions between vitamin D(2), vitamin D(3), and vitamin D analogs. Annu Rev Nutr 33: 23-44, 2013
98. Kantham L, Quinn SJ, Egbuna OI, Baxi K, Butters R, Pang JL, Pollak MR, Goltzman D, Brown EM. The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Endocrinol Metab 297: E915-923, 2009
99. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64: 441-450, 2003
100. KDIGO. Clinical practice guidelines for the management of CKDMBD. Kidney Int 76: S1-S130, 2009
101. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
102. 3 upregulates FGF23 gene expression in bone: The final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042, 2005
103. Kos CH, KaraplisAC, Peng JB, HedigerMA, Goltzman D, Mohammad KS, Guise TA, Pollak MR. The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest 111: 1021-1028, 2003
104. Krajisnik T, Olauson H, Mirza MA, Hellman P, Akerstrom G, Westin G, Larsson TE, Bjorklund P. Parathyroid Klotho and FGF-receptor 1 expression declinewith renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 78: 1024-1032, 2010
105. Krupp K, Madhivanan P. FGF23 and risk of all-cause mortality and cardiovascular events: A meta-analysis of prospective cohort studies. Int J Cardiol 176: 1341-1342, 2014
106. Kuro-o M. Overview of the FGF23-Klotho axis. Pediatr Nephrol 25: 583-590, 2010
107. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997
108. Lambers TT, Oancea E, de Groot T, Topala CN, Hoenderop JG, Bindels RJ. Extracellular pH dynamically controls cell surface delivery of functional TRPV5 channels. Mol Cell Biol 27: 1486-1494, 2007
109. Lambert PW, Stern PH, Avioli RC, Brackett NC, Turner RT, Greene A, Fu IY, Bell NH. Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man. J Clin Invest 69: 722-725, 1982
110. Lameris AL, Nevalainen PI, Reijnen D, Simons E, Eygensteyn J, Monnens L, Bindels RJ, Hoenderop JG. Segmental transport of Ca(2)(+) andMg(2)(+) along the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 308: G206-G216, 2015
111. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882-F889, 2010
112. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882-F889, 2010
113. Lederer ED, Khundmiri SJ, Weinman EJ. Role of NHERF-1 in regulation of the activity of Na-K ATPase and sodium-phosphate co-transport in epithelial cells. J Am Soc Nephrol 14: 1711-1719, 2003
114. Lee J, Cha SK, Sun TJ, Huang CL. PIP2 activates TRPV5 and releases its inhibition by intracellular Mg2+. J Gen Physiol 126: 439-451, 2005
115. Lee M, Partridge NC. Parathyroid hormone signaling in bone and kidney. Curr Opin Nephrol Hypertens 18: 298-302, 2009
116. 3 controls a cohort of vitamin D receptor target genes in the proximal intestine that is enriched for calcium-regulating components. J Biol Chem 290: 18199-18215, 2015
117. Li Y, Song YH, Rais N, Connor E, Schatz D, Muir A, Maclaren N. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism [see comments]. J Clin Invest 97: 910-914, 1996
118. Lieben L, Benn BS, Ajibade D, Stockmans I, Moermans K, Hediger MA, Peng JB, Christakos S, Bouillon R, Carmeliet G. Trpv6 mediates intestinal calcium absorption during calcium restriction and contributes to bone homeostasis. Bone 47: 301-308, 2010
119. Liu N, Nguyen L, Chun RF, Lagishetty V, Ren S, Wu S, Hollis B, DeLuca HF, Adams JS, Hewison M. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology 149: 4799-4808, 2008
120. 2+ channels TRPV5 and TRPV6. Nephrol Dial Transplant 23: 3397-3402, 2008
121. Malluche H, Werner E, Ritz E. Intestinal absorption of calicum and whole-body calcium retention in incipient and advanced renal failure. Miner Electrolyte Metab 1: 263-270, 1978
122. Martino NA, Reshkin SJ, Ciani E, Dell'Aquila ME. Calcium-sensing receptor-mediated osteogenic and early-stage neurogenic differentiation in umbilical cord matrix mesenchymal stem cells from a large animal model. PLoS One 9: e111533, 2014
123. Masuyama R. Role of local vitamin D signaling and cellular calcium transport system in bone homeostasis. J Bone Miner Metab 32: 1-9, 2014
124. Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska KA. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 18: 122-130, 2007
125. Matkovic V, Goel PK, Badenhop-Stevens NE, Landoll JD, Li B, Ilich JZ, Skugor M, Nagode LA, Mobley SL, Ha EJ, Hangartner TN, Clairmont A. Calcium supplementation and bone mineral density in females from childhood to young adulthood: A randomized controlled trial. Am J Clin Nutr 81: 175-188, 2005
126. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, and Kidney Disease: Improving Global O. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
127. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drueke TB, and Evaluation of Cinacalcet HTtLCETI. Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial. J Am Soc Nephrol 26: 1466-1475, 2015
128. Moe SM, Chen NX, Newman CL, Gattone VH, II, Organ JM, Chen X, Allen MR. Acomparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res 29: 902-910, 2014
129. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS, White KE, Gattone VH, II. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 75: 176-184, 2009
130. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 1: 697-703, 2006
131. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drueke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J, and Evaluation of Cinacalcet HTtLCETI. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 132: 27-39, 2015
132. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63: 1003-1011, 2003
133. Moe SM, SeifertMF, Chen NX, Sinders RM, Chen X, Duan D, Henley C, Martin D, Gattone VH, II. R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant 24: 2371-2377, 2009
134. Moe SM, Sprague S. Mineral bone disorders in chronic kidney disease. In: Brenner B, editor. The Kidney. Philadelphia, PA: Elsevier, 2016, pp. 1822-1853
135. Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M. Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease. Clin Calcium 15(Suppl 1): 35-39; discussion 39-40, 2005
136. Naveh-Many T, Friedlaender MM, Mayer H, Silver J. Calcium regulates parathyroid hormone messenger ribonucleic acid (mRNA), but not calcitonin mRNA in vivo in the rat. Dominant role of 1, 25-dihydroxyvitamin D. Endocrinology 125: 275-280, 1989
137. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 86: 1313-1319, 1990
138. NechamaM, Ben-Dov IZ, Silver J, Naveh-Many T. Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD. Am J Physiol Renal Physiol 296: F795-F800, 2009
139. Negri AL. The klotho gene: A gene predominantly expressed in the kidney is a fundamental regulator of aging and calcium/phosphorus metabolism. J Nephrol 18: 654-658, 2005
140. Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhaes AO, Custodio MR, Batista DG, Jorgetti V, Moyses RM. Vascular calcification: Contribution of parathyroid hormone in renal failure. Kidney Int 71: 1262-1270, 2007
141. Nigwekar SU, Tamez H, Thadhani RI. Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). BoneKEy Rep 3: 2014
142. 2+ and Mg2+ transport proteins. J Am Soc Nephrol 17: 617-626, 2006
143. Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, Benchitrit J, Machado dos Reis L, Edelman A, Lacour B, Jorgetti V, Drueke TB, Massy ZA. Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant 27: 505-513, 2012
144. 2+. Cell Calcium 29: 417-428, 2001
145. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 67: 929-936, 1988
146. Olauson H, Lindberg K, Amin R, Sato T, Jia T, Goetz R, Mohammadi M, Andersson G, Lanske B, Larsson TE. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet 9: e1003975, 2013
147. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. JAMA 305: 1119-1127, 2011
148. Parfitt AM. Plasma calcium control at quiescent bone surfaces: A new approach to the homeostatic function of bone lining cells. Bone 10: 87-88, 1989
149. Parfitt AM. Targeted and nontargeted bone remodeling: Relationship to basic multicellular unit origination and progression. Bone 30: 5-7, 2002
150. Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Dehmel B, Trotman ML, Modafferi DM, Goodman WG. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The EVOLVE trial. J Clin Endocrinol Metab 98: 4834-4844, 2013
151. Parfrey PS, Drueke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM, and Evaluation of Cinacalcet HTtLCETI. The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol 10: 791-799, 2015
152. Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335: 1115-1122, 1996
153. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 26: 622-631, 1995
154. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51: 952-965, 2008
155. Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 13: 134-141, 2004
156. Ramirez JA, Goodman WG, Gornbein J, Menezes C, Moulton L, Segre GV, Salusky IB. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 76: 1489-1494, 1993
157. Ren S, Nguyen L, Wu S, Encinas C, Adams JS, Hewison M. Alternative splicing of vitamin D-24-hydroxylase: A novel mechanism for the regulation of extrarenal 1, 25-dihydroxyvitamin D synthesis. J Biol Chem 280: 20604-20611, 2005
158. Renkema KY, Velic A, Dijkman HB, Verkaart S, van der Kemp AW, Nowik M, Timmermans K, Doucet A, Wagner CA, Bindels RJ, Hoenderop JG. The calcium-sensing receptor promotes urinary acidification to prevent nephrolithiasis. J Am Soc Nephrol 20: 1705-1713, 2009
159. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-DechentW, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15: 2857-2867, 2004
160. Riccardi D, Brennan SC, Chang W. The extracellular calcium-sensing receptor, CaSR, in fetal development. Best Pract Res Clin Endocrinol Metab 27: 443-453, 2013
161. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 70: 654-659, 2006
162. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, Martinez-Moreno JM, Ramirez AP, Pineda C, Canalejo A, Jaeger P, Aguilera-Tejero E, Rodriguez M, Felsenfeld A, Almaden Y. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 23: 1190-1197, 2012
163. 2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nat Commun 3: 1329, 2012
164. Rudnicki MA, Williams BO. Wnt signaling in bone and muscle. Bone 80: 60-66, 2015
165. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72: 1255-1261, 2007
166. Saint-Criq V, Rapetti-Mauss R, Yusef YR, Harvey BJ. Estrogen regulation of epithelial ion transport: Implications in health and disease. Steroids 77: 918-923, 2012
167. Satoh M, Nagasu H, Morita Y, Yamaguchi TP, Kanwar YS, Kashihara N. Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling. Am J Physiol Renal Physiol 303: F1641-F1651, 2012
168. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, XiaX, LiX, HenleyC, Eschenberg M, RichardsWG. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 122: 2543-2553, 2012
169. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate. Circ Res 109: 697-711, 2011
170. Shi Y, Gou BD, Shi YL, Zhang TL, Wang K. Lanthanum chloride suppresses hydrogen peroxide-enhanced calcification in rat calcifying vascular cells. Biometals 22: 317-327, 2009
171. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004
172. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004
173. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505, 2001
174. Shimizu T, Yoshitomi K, Nakamura M, Imai M. Effects of PTH, calcitonin, and cAMPon calcium transport in rabbit distal nephron segments. Am J Physiol 259: F408-F414, 1990
175. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118: 1748-1757, 2008
176. Silva BC, Bilezikian JP. Parathyroid hormone: Anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol 22: 41-50, 2015
177. Silver J, Naveh-Many T. Phosphate and the parathyroid. Kidney Int 75: 898-905, 2009
178. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78: 1296-1301, 1986
179. Slatopolsky E, Bricker NS. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4: 141-145, 1973
180. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97: 2534-2540, 1996
181. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315: 157-161, 1986
182. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J. Long-term effects of calcium carbonate and 2. 5 mEq/liter calcium dialysate on mineralmetabolism. Kidney Int 36: 897-903, 1989
183. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1, 25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74: 2136-2143, 1984
184. Smith RC, O'Bryan LM, Farrow EG, Summers LJ, Clinkenbeard EL, Roberts JL, Cass TA, Saha J, Broderick C, Ma YL, Zeng QQ, Kharitonenkov A, Wilson JM, Guo Q, Sun H, Allen MR, Burr DB, Breyer MD, White KE. Circulating alphaKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest 122: 4710-4715, 2012
185. Song S, Gao P, Xiao H, Xu Y, Si LY. Klotho suppresses cardiomyocyte apoptosis in mice with stress-induced cardiac injury via downregulation of endoplasmic reticulum stress. PLoS One 8: e82968, 2013
186. Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, Frutkin A, Dichek D, Giachelli CM. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 104: 733-741, 2009
187. Spence LA, Lipscomb ER, Cadogan J, Martin B, WastneyME, Peacock M, Weaver CM. The effect of soy protein and soy isoflavones on calcium metabolism in postmenopausal women: A randomized crossover study. Am J Clin Nutr 81: 916-922, 2005
188. Sprague SM, Moe SM. The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol 8: 313-318, 2012
189. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15: 770-779, 2004
190. Sutton RA, Dirks JH. The renal excretion of calcium: A review of micropuncture data. Can J Physiol Pharmacol 53: 979-988, 1975
191. Takasu H, Guo J, Bringhurst FR. Dual signaling and ligand selectivity of the human PTH/PTHrP receptor. J Bone Miner Res 14: 11-20, 1999
192. Takeshita K, Fujimori T, Kurotaki Y, Honjo H, Tsujikawa H, Yasui K, Lee JK, Kamiya K, Kitaichi K, Yamamoto K, Ito M, Kondo T, Iino S, Inden Y, Hirai M, Murohara T, Kodama I, Nabeshima Y. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation 109: 1776-1782, 2004
193. Talmage DW, Talmage RV. Calcium homeostasis: How bone solubility relates to all aspects of bone physiology. J Musculoskelet Neuronal Interact 7: 108-112, 2007
194. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519-530, 2008
195. Toka HR, Pollak MR, Houillier P. Calcium sensing in the renal tubule. Physiology (Bethesda) 30: 317-326, 2015
196. Tokumoto M, Mizobuchi M, Finch JL, Nakamura H, Martin DR, Slatopolsky E. Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: Sevelamer carbonate prevents vascular calcification. Am J Nephrol 29: 582-591, 2009
197. Torres PU, Prie D, Molina-Bletry V, Beck L, Silve C, Friedlander G. Klotho: An antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 71: 730-737, 2007
198. Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, Girgis M, Vincent RJ, Wetmore LA, Dawn B, Bonewald LF, Stubbs JR, Wacker MJ. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 304: E863-E873, 2013
199. Tyler Miller R. Control of renal calcium, phosphate, electrolyte, and water excretion by the calcium-sensing receptor. Best Pract Res Clin Endocrinol Metab 27: 345-358, 2013
200. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774, 2006
201. 2+. J Steroid Biochem Mol Biol 89-90: 303-308, 2004
202. 2+-controlled recycling pathway. J Biol Chem 283: 4077-4086, 2008
203. Wetmore JB, Santos PW, Mahnken JD, Krebill R, Menard R, Gutta H, Quarles LD. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J Clin Endocrinol Metab 96: E57-64, 2011
204. White KE, Hum JM, Econs MJ. Hypophosphatemic rickets: Revealing novel control points for phosphate homeostasis. Curr Osteoporos Rep 12: 252-262, 2014
205. 2+ absorption. Am J Physiol Gastrointest Liver Physiol 303: G879-G885, 2012
206. Xie J, Cha SK, An SW, Kuro OM, Birnbaumer L, Huang CL. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun 3: 1238, 2012
207. 3 exerts a skeletal anabolic effect and improves mineral ion homeostasis in mice that are homozygous for both the 1alpha-hydroxylase and parathyroid hormone null alleles. Endocrinology 147: 4801-4810, 2006
208. Xue Y, Xiao Y, Liu J, Karaplis AC, Pollak MR, Brown EM, Miao D, Goltzman D. The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice. Am J Physiol Endocrinol Metab 302: E841-E851, 2012
209. Yeh BI, Kim YK, Jabbar W, Huang CL. Conformational changes of pore helix coupled to gating of TRPV5 by protons. EMBO J 24: 3224-3234, 2005
210. Yeh BI, Sun TJ, Lee JZ, Chen HH, Huang CL. Mechanism and molecular determinant for regulation of rabbit transient receptor potential type 5 (TRPV5) channel by extracellular pH. J Biol Chem278: 51044-51052, 2003
211. Yu AS. Claudins and the kidney. J Am Soc Nephrol 26: 11-19, 2015
212. Zella LA, Shevde NK, Hollis BW, Cooke NE, Pike JW. Vitamin D-binding protein influences total circulating levels of 1, 25-dihydroxyvitaminD3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology 149: 3656-3667, 2008
213. 3 plus nicotine in rats. Exp Biol Med (Maywood) 234: 908-917, 2009